|Editorial  board | About the Journal   | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code |   Contact  |
 

Acta Medica Medianae
Vol. 48, No2 , April, 2009
UDK 61
YU ISSN 0365-4478

 

Correspondence to:
Vanja Pecic

120/13 Vizantijski Blvd.  Nis

Phone: 064/2160035

E-mail: acrepus@medianis.net

 

 

 

 

 

 

Review article
UDC:616.36-006.6:616.36-002

 

The role of Hepatitis C virus in Hepatocellular carcinoma pathogenesis – a problem of modern man

 

Vanja Pecic, Milica Nestorovic, Milan Radojkovic and Bojan Ilic

 

 Clinic of Surgery, Clinical Center Nis

 

People with hepatitis C virus (HCV) have a 2% annual risk, and a 7% to 14% five-year risk for hepatocellular carcinoma development, a tumor with an estimated median survival of 4.3 to 20 months after making the diagnosis. HCV is the cause of: 20% of acute hepatitis, 70% of chronic hepatitis, 40% of liver cirrhosis, 60% of hepatocellular carcinomas (HCC), and 30% of indications for liver transplantation. HCC is the fifth most common cancer in the world, and is one of the most frequent causes of death, accounting for 6% of all carcinomas. There is a heterogeneous distribution of HCC worldwide. It develops after the mutations in cell machinery causing the cell to reproduce faster and/or to avoid apoptosis. Current researches include the search for the genes that are disregulated in HCC, protein markers, and other predictive biomarkers. As similar research is yielding results in various other malignant diseases, it is hoped that identifying the aberrant genes and the resultant proteins could lead to the identification of pharmacological interventions for HCC.Acta Medica Medianae 2009;48(2):32-36.

 

Key words: hepatitis C virus, hepatocellular carcinoma